TRPV4 antagonists ameliorate ventriculomegaly in a rat model of hydrocephalus.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 32938829.
- Also identified by DOI 10.1172/jci.insight.137646 and PMC identifier 7526552.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Hydrocephalus is a serious condition that impacts patients of all ages. The standards of care are surgical options to divert, or inhibit production of, cerebrospinal fluid; to date, there are no effective pharmaceutical treatments, to our knowledge. The causes vary widely, but one commonality of this condition is aberrations in salt and fluid balance. We have used a genetic model of hydrocephalus to show that ventriculomegaly can be alleviated by inhibition of the transient receptor potential vanilloid 4, a channel that is activated by changes in osmotic balance, temperature, pressure and inflammatory mediators. The TRPV4 antagonists do not appear to have adverse effects on the overall health of the WT or hydrocephalic animals.
Medical subject headings
- Cerebral Cortex
- Disease Models, Animal
- Hydrocephalus
- Morpholines
- Nervous System Malformations
- Pyrroles
- TRPV Cation Channels